SRx Health Solutions and EMJX Invest in Recent IPO and Commercial-Stage Pharmaceutical Company of Psychedelics, Optimi Health Corp. (OPTH)
Rhea-AI Summary
SRx Health Solutions (NYSE American: SRXH) and merger partner EMJX have invested in Optimi Health (NASDAQ: OPTH), a commercial-stage pharmaceutical company producing GMP-grade psychedelic drug products such as psilocybin for mental health therapies.
The investment was identified by EMJX’s AI-driven platform, citing about 30% insider ownership, institutional participation, strong management insider IPO participation, and governance led by chairman John James (JJ) Wilson. Tailwinds include an April 2026 U.S. executive order to accelerate psychedelic drug development. SRx has filed a Form S-4 related to its proposed merger with EMJX.
Positive
- EMJX AI platform selects Optimi Health as an investment opportunity
- Optimi Health insider ownership of approximately 30%
- Optimi Health has about 5.6 million shares outstanding
- Institutional and management insider participation in Optimi Health IPO
- Industry support from April 2026 U.S. executive order on psychedelics
- SRx files Form S-4 for proposed merger with EMJX
Negative
- None.
News Market Reaction – SRXH
In the May 21 session, SRXH gained 9.79%, reflecting a notable positive market reaction. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Profit dividend plan | Positive | -9.4% | Plan to dividend 75% of profits from Astro Investment XVII to shareholders. |
| May 14 | Earnings update | Positive | -9.4% | Q2 2026 results with higher revenue, better margins, and improved losses. |
| May 13 | AI/space investment | Positive | +25.8% | Investment of over 10% of investable capital into Astro Investment XVII SPV. |
| Apr 22 | Astro capital stake | Positive | +1.7% | Investment exceeding 10% of investable capital into AI and space‑focused SPV. |
| Apr 17 | Merger update | Positive | -0.6% | Shareholder letter on EMJX merger progress and strong digital‑asset returns. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows SRXH often experiencing negative or muted price reactions to seemingly positive strategic and financial updates.
Over the past months, SRx Health has focused on an all‑stock acquisition of EMJ Crypto Technologies and strategic investments, including allocating more than 10% of investable capital to Astro Investment XVII and emphasizing AI and space themes. Earnings for fiscal Q2 2026 showed net revenue of $3.4 million and improved losses, yet shares fell about 9.42% after both the earnings release and a profit‑sharing dividend update. Today’s IPO‑related investment news continues the pattern of thematic, capital‑deployment announcements alongside a still weak longer‑term chart.
Key Terms
gmp-grade medical
psychedelic medical
psilocybin medical
executive order regulatory
registration statement on form s-4 regulatory
information statement/prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORTH PALM BEACH, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platform with which the Company has entered into a definitive merger agreement, today announced investing in Optimi Health Corp. (NASDAQ: OPTH), a commercial-stage pharmaceutical company focused on manufacturing and distribution of GMP-grade psychedelic drug products for mental health therapies including Psilocybin.
The EMJX proprietary operating system applying quantitative models, artificial intelligence and systematic risk controls has identified Optimi Health Corp. as an investment opportunity for several reasons including high insider ownership of approximately
Additionally, the psychedelic industry is experiencing tailwinds after U.S. President Trump signed an executive order in April 2026 to accelerate psychedelic drug development and improve timelines and coordination with the FDA and DEA.
“Our proprietary AI technology investment platform can guide and identify investment themes,” said Michael Young, SRx Board Member. “This gives us a unique opportunity to invest in companies with positive macro and industry trends. Optimi has approximately 5.6 million shares outstanding, institutional ownership, as well as strong participation by management insiders on the IPO.”
Additional Information and Where to Find It
In connection with the proposed transaction between the Company has filed with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the common stock to be issued in connection with the proposed transaction. The Registration Statement includes an information statement of the Company and a prospectus of the Company (the "Information Statement/Prospectus"), and each of EMJX and the Company may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Information Statement/Prospectus will be sent to the stockholders This is not a substitute for the Registration Statement, the Information Statement/Prospectus or any other relevant documents that EMJX or the Company has filed or will file with the SEC. BEFORE MAKING ANY INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND INFORMATION STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT EMJX, THE COMPANY, THE PROPOSED TRANSACTION, AND RELATED MATTERS. A copy of the Registration Statement, Information Statement/Prospectus, as well as other relevant documents filed by EMJX and the Company with the SEC, may be obtained free of charge, when they become available, at the SEC's website at www.sec.gov. The information on EMJX's or the Company's respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.
No Offer or Solicitation
This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "intend," "aim," "plan," "may," "could," "target," and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.
Company Contact
SRx Health Solutions, Inc.
Kent Cunningham, Chief Executive Officer
Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
valter@kcsa.com
